Tags

Type your tag names separated by a space and hit enter

Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form.
J Pharm Biomed Anal 2007; 43(2):722-6JP

Abstract

A simple, selective, precise and stability-indicating high-performance thin-layer chromatographic method of analysis of imatinib mesylate both as a bulk drug and in formulations was developed and validated. The method employed HPTLC aluminium plates precoated with silica gel 60F-254 as the stationary phase. The solvent system consisted of chloroform:methanol (6:4, v/v). The system was found to give compact spot for imatinib mesylate (R(f) value of 0.53+/-0.02). Densitometric analysis of imatinib mesylate was carried out in the absorbance mode at 276 nm. The linear regression analysis data for the calibration plots showed good linear relationship with r(2)=0.9966+/-0.0013 with respect to peak area in the concentration range 100-1000 ng per spot. The mean value+/-S.D. of slope and intercept were 164.85+/-0.72 and 1168.3+/-8.26 with respect to peak area. The method was validated for precision, recovery and robustness. The limits of detection and quantitation were 10 and 30 ng per spot, respectively. Imatinib mesylate was subjected to acid and alkali hydrolysis, oxidation and thermal degradation. The drug undergoes degradation under acidic, basic, oxidation and heat conditions. This indicates that the drug is susceptible to acid, base hydrolysis, oxidation and heat. Statistical analysis proves that the method is repeatable, selective and accurate for the estimation of said drug. The proposed developed HPTLC method can be applied for identification and quantitative determination of imatinib mesylate in bulk drug and dosage forms.

Authors+Show Affiliations

Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka 576104, India.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Validation Studies

Language

eng

PubMed ID

16920319

Citation

Vadera, N, et al. "Stability-indicating HPTLC Determination of Imatinib Mesylate in Bulk Drug and Pharmaceutical Dosage Form." Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 2, 2007, pp. 722-6.
Vadera N, Subramanian G, Musmade P. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. J Pharm Biomed Anal. 2007;43(2):722-6.
Vadera, N., Subramanian, G., & Musmade, P. (2007). Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. Journal of Pharmaceutical and Biomedical Analysis, 43(2), pp. 722-6.
Vadera N, Subramanian G, Musmade P. Stability-indicating HPTLC Determination of Imatinib Mesylate in Bulk Drug and Pharmaceutical Dosage Form. J Pharm Biomed Anal. 2007 Jan 17;43(2):722-6. PubMed PMID: 16920319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. AU - Vadera,N, AU - Subramanian,G, AU - Musmade,P, Y1 - 2006/08/22/ PY - 2006/04/03/received PY - 2006/07/10/revised PY - 2006/07/11/accepted PY - 2006/8/22/pubmed PY - 2007/7/10/medline PY - 2006/8/22/entrez SP - 722 EP - 6 JF - Journal of pharmaceutical and biomedical analysis JO - J Pharm Biomed Anal VL - 43 IS - 2 N2 - A simple, selective, precise and stability-indicating high-performance thin-layer chromatographic method of analysis of imatinib mesylate both as a bulk drug and in formulations was developed and validated. The method employed HPTLC aluminium plates precoated with silica gel 60F-254 as the stationary phase. The solvent system consisted of chloroform:methanol (6:4, v/v). The system was found to give compact spot for imatinib mesylate (R(f) value of 0.53+/-0.02). Densitometric analysis of imatinib mesylate was carried out in the absorbance mode at 276 nm. The linear regression analysis data for the calibration plots showed good linear relationship with r(2)=0.9966+/-0.0013 with respect to peak area in the concentration range 100-1000 ng per spot. The mean value+/-S.D. of slope and intercept were 164.85+/-0.72 and 1168.3+/-8.26 with respect to peak area. The method was validated for precision, recovery and robustness. The limits of detection and quantitation were 10 and 30 ng per spot, respectively. Imatinib mesylate was subjected to acid and alkali hydrolysis, oxidation and thermal degradation. The drug undergoes degradation under acidic, basic, oxidation and heat conditions. This indicates that the drug is susceptible to acid, base hydrolysis, oxidation and heat. Statistical analysis proves that the method is repeatable, selective and accurate for the estimation of said drug. The proposed developed HPTLC method can be applied for identification and quantitative determination of imatinib mesylate in bulk drug and dosage forms. SN - 0731-7085 UR - https://www.unboundmedicine.com/medline/citation/16920319/Stability_indicating_HPTLC_determination_of_imatinib_mesylate_in_bulk_drug_and_pharmaceutical_dosage_form_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0731-7085(06)00474-2 DB - PRIME DP - Unbound Medicine ER -